ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
High co-infection burden and ICU-specific pathogen profiles in pediatric Candida albicans respiratory infections: a large-scale tNGS analysis.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative clinical outcomes of pandrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections in children.BMC infectious diseases · 2026Article
- Clinical and Microbiological Characteristics of Pulmonary Aspergillosis in Elderly vs Non-Elderly Patients: A tNGS-Based Retrospective Study.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundCandida albicans is a significant opportunistic pathogen in pediatric respiratory infections, yet systematic analyses of its role in hospitalized children remain scarce. This study evaluates the prevalence, clinical profiles, and outcomes of C. albicans-associated respiratory infections in this population.
methodsFrom April 2021 to December 2024, 10,310 pediatric inpatients with respiratory infections at Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital underwent pathogen screening via targeted next-generation sequencing (tNGS).
resultsC. albicans was detected in 5.0% (511/10,310), with detection rates varying by specimen: highest in sputum (10.3%), followed by bronchoalveolar lavage fluid (8.8%), and minimal in throat swabs (0.3%). Co-infections occurred in 99.0% (506/511), predominantly involving Mycoplasma pneumoniae (189), Haemophilus influenzae (174), and Rhinovirus (169). ICU patients (6.3%) demonstrated elevated inflammatory markers (PCT: 0.31 vs. 0.08 ng/mL; D-dimer: 795 vs. 360 ng/mL FEU; P < 0.001), prolonged hospitalization (median 17 vs. 7 days, P < 0.001), and distinct pathogens (Acinetobacter baumannii vs. M. pneumoniae in non-ICU). 51.7% and 35.4% of the children experienced respiratory and other systemic complications, respectively. Among the 511 children diagnosed with C. albicans infection, 32 (6.3%) required ICU admission for monitoring. The median duration of hospitalization for these 511 children was 7 days. Of these, 482 (94.3%) recovered and were discharged following treatment, while 26 (5.0%) had family members who requested voluntary discharge due to unsatisfactory outcomes or other reasons. Unfortunately, 3 children (0.6%) died despite receiving intensive medical treatment.
conclusionThis large-scale tNGS-based study addresses critical knowledge gaps, revealing ICU-specific pathogen profiles (A. baumannii), high co-infection burdens (99.0%), and complications linked to prematurity/immunodeficiency. The predominance of lower respiratory tract involvement (sputum/BALF positivity) underscores the need for specimen-selective diagnostics. Findings advocate for optimized tNGS protocols, ICU-tailored antimicrobial strategies, and early interventions in high-risk subgroups to reduce morbidity (e.g., sepsis risk) and socioeconomic burdens.
Indexed as
Identifiers
40679578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.